Company news
Innovation Pharmaceuticals Inc. news in 2016
Innovation Pharmaceuticals Inc.'s news releases, calls and decks from 2016, newest first.
Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on Partnerships
December 22, 2016
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening
December 19, 2016
Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment; Company Seeks to Develop World’s First p53-Modulating Oral Cancer Drug
December 15, 2016
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
December 7, 2016
Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results
November 14, 2016
Cellceutix Announces Business Update Call at 10AM Eastern on November 15
November 9, 2016
Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis
October 31, 2016
Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
October 26, 2016
Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
October 10, 2016
Cellceutix Announces Appointment of Vice President for Regulatory Affairs
September 16, 2016
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
September 13, 2016
Cellceutix Corporation to Present at Upcoming Conferences
September 7, 2016
Cellceutix Further Expands Its Senior Management Team With the Addition of an Industry Veteran
August 30, 2016
Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
August 3, 2016
Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
July 21, 2016
Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis
July 18, 2016
Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis
July 7, 2016
Cellceutix Corporation Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer
June 30, 2016